Tramadol pretreatment for reducing etomidate resulted myoclonus and severity

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-PPD-16009008

Enrollment

Unknown

Registered

2016-08-10

Start date

2016-08-10

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myoclonus induced by etomidate

Interventions

T0-T2:tramodol pretreatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients aged 30-70 years old; (2) the American society of anesthesiologists (ASA) class I - II; (3) the body mass index (BMI) of 18 to 24 kg/m2;(4) the hemoglobin (HGB) > 100 g/L; (5) total protein (TP) > 60 g/L; (6) serious circulation, respiratory disease, endocrine and neuromuscular system; (7) Mallampati classification: I - II level; (8) with no history of cervical spine;

Exclusion criteria

Exclusion criteria: (1) with severe liver and kidney dysfunction; (2) electrolyte disorder; (3) used sedatives or analgesics in 24 hours; (4) Within a month preoperative used drugs affect nerve muscle function; (5) the abuse of psychiatric drugs or long-term use of steroid hormone drugs; (6) steroid, benzyl ammonium quarterly isoquinoline kind drug allergy history; (7) allergy for etomidate or fat milk; (8) Take part in other clinical trials;

Design outcomes

Primary

Measure	Time frame
myoclonus classification;	—

Countries

China

Contacts

Public ContactZhigang Liu

People's Hospital, Wuhan University

28662470@qq.com+86 13667169966

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026